NO20082101L - Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer - Google Patents

Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer

Info

Publication number
NO20082101L
NO20082101L NO20082101A NO20082101A NO20082101L NO 20082101 L NO20082101 L NO 20082101L NO 20082101 A NO20082101 A NO 20082101A NO 20082101 A NO20082101 A NO 20082101A NO 20082101 L NO20082101 L NO 20082101L
Authority
NO
Norway
Prior art keywords
optionally substituted
group
alkyl group
rog
rer
Prior art date
Application number
NO20082101A
Other languages
English (en)
Other versions
NO341055B1 (no
Inventor
Graeme Caameron Murray Smith
Marc Geoffrey Hummersone
Sylvie Gomez
Keith Allan Menear
Karine Malagu
Heather Mary Ellen Duggan
Xiao-Ling Fan Cockcroft
Gesine Johanna Hermann
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37533284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082101(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0524047A external-priority patent/GB0524047D0/en
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of NO20082101L publication Critical patent/NO20082101L/no
Publication of NO341055B1 publication Critical patent/NO341055B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Det tilveiebringes en forbindelse med formel I: hvor: én eller to av X, Xog Xer N og den andre er CH; Rer valgt fra halogen, OR, SR, NRR, NRC(=0)R, NRS0R, en eventuelt substituert C.o heteroarylgruppe eller en eventuelt substituert C.o arylgruppe, hvor Rog Rer valgt fra H, en eventuelt substituert C.arylgruppe, en eventuelt substituert C.heteroarylgruppe eller en eventuelt substituert Ci .7 alkylgruppe;og Rer uavhengig valgt fra H, en eventuelt substituert C.alkylgruppe, en eventuelt substituert C5.20 heteroarylgruppe, en eventuelt substituert C.arylgruppe ellerog Rsammen med nitrogenet hvortil de er bundet danner en heterocyklisk ring inneholdende mellom 3 og 8 ringatomer; Rer valgt fra H, en eventuelt substituert C.arylgruppe, en eventuelt substituert C.heteroarylgruppe, en eventuelt substituert C.alkylgruppe eller NR, hvorog Rer uavhengig valgt fra H, en eventuelt substituert C.alkylgruppe, en eventuelt substituert C5.20 heteroarylgruppe, en eventuelt substituert C.arylgruppe eller Rog Rsammen med nitrogenet hvor til de er bundet danner en heterocyklisk ring inneholdende mellom 3 og 8 ringatomer; Rer valgt fra H, en eventuelt substituert C.arylgruppe, en eventuelt substituert C5.20 heteroarylgruppe eller en eventuelt substituert Ci.alkylgruppe; Rog Rer valgt fra H og en C-alkylgruppe;og R, sammen med nitrogenet hvor til de er bundet, danner en heterocyklisk ring inneholdende mellom 3 og 8 ringatomer; Rer valgt fra H, halogen, OR, SR, NRR, en eventuelt substituert C5.20 heteroarylgruppe og en eventuelt substituert C.arylgruppe, hvor Rog Rer valgt fra H, en eventuelt substituert C.arylgruppe, en eventuelt substituert C.heteroarylgruppe eller en eventuelt substituert C.alkylgruppe;; Rog R6 er uavhengig valgt fra H, en eventuelt substituert C.alkylgruppe, en eventuelt substituert C.heteroarylgruppe og en eventuelt substituert C.arylgruppe ellerog Rsammen med nitrogenet hvortil de er bundet danner en heterocyklisk ring inneholdende mellom 3 og 8 ringatomer eller et farmasøytisk akseptabelt salt derav, med det forbehold at når Rer usubstituert morfolino, Rog Rsammen med nitrogenatomet som de er bundet til danner en usubstituert morfolino og Rer usubstituert fenyl og Xer CH, da er Xikke N og Xer ikke CH eller Xer ikke CH og Xer ikke N og nårer usubstituert piperidinyl, Rra og Rsammen med nitrogenatomet som de er bundet til danner en usubstituert piperidinyl og Rer usubstituert fenyl og Xer CH, da er Xikke CH og Xer ikke N. Det er også gitt fremgangsmåter for fremstilling av en forbindelse med formelen 1 og anvendelse av en forbindelse med formelen 1 som et medikament og ved behandling av kreft.
NO20082101A 2005-11-22 2008-05-06 Pyridopyrimidinforbindelser og anvendelse derav,samt farmasøytisk preparat. NO341055B1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US73890205P 2005-11-22 2005-11-22
GB0524047A GB0524047D0 (en) 2005-11-25 2005-11-25 Compounds
US82330806P 2006-08-23 2006-08-23
US82330906P 2006-08-23 2006-08-23
PCT/GB2006/004327 WO2007060404A1 (en) 2005-11-22 2006-11-20 PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS

Publications (2)

Publication Number Publication Date
NO20082101L true NO20082101L (no) 2008-08-15
NO341055B1 NO341055B1 (no) 2017-08-14

Family

ID=37533284

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082101A NO341055B1 (no) 2005-11-22 2008-05-06 Pyridopyrimidinforbindelser og anvendelse derav,samt farmasøytisk preparat.

Country Status (16)

Country Link
US (1) US20080194546A1 (no)
EP (1) EP1954699B1 (no)
JP (1) JP5161102B2 (no)
KR (1) KR101464384B1 (no)
AR (1) AR057626A1 (no)
AU (1) AU2006318948B2 (no)
CA (1) CA2628920C (no)
EC (1) ECSP088536A (no)
HK (1) HK1124039A1 (no)
HR (1) HRP20120963T1 (no)
IL (1) IL191196A (no)
NO (1) NO341055B1 (no)
PL (1) PL1954699T3 (no)
TW (1) TWI452047B (no)
UY (1) UY29938A1 (no)
WO (1) WO2007060404A1 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006330924B2 (en) * 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
CN101558067B (zh) * 2006-08-23 2014-05-28 库多斯药物有限公司 作为mtor抑制剂的2-甲基吗啉吡啶并、吡唑并和嘧啶并-嘧啶衍生物
MX2009001946A (es) * 2006-08-23 2009-03-05 Kudos Pharm Ltd Derivados de 2-metilmorfolin-pirido-, pirazo- y pirimido- pirimidina como inhibidores de mtor.
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
CA2702315A1 (en) * 2007-10-15 2009-04-23 Astrazeneca Ab Combination 059
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2262504A1 (en) * 2008-02-21 2010-12-22 AstraZeneca AB Combination therapy 238
EP2303875B1 (en) 2008-06-20 2012-11-28 AstraZeneca AB Compositions with and process for methylmorpholin-subsituted pyrido[2,3-d]pyrimidines
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
ES2432821T3 (es) * 2008-07-31 2013-12-05 Genentech, Inc. Compuestos de pirimidina, composiciones y métodos de utilización
WO2010049481A1 (en) * 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2781210A1 (en) 2009-11-18 2011-05-26 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
WO2011067356A2 (en) 2009-12-03 2011-06-09 Novartis Ag Polymorphs of a mek inhibitor
UA110697C2 (uk) 2010-02-03 2016-02-10 Сігнал Фармасьютікалз, Елелсі ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK
BR112012019635A2 (pt) * 2010-02-22 2016-05-03 Hoffmann La Roche compostos inibidores de pirido[3,2-d] pirimidina pi3k delta e métodos de uso
BR112012024585A2 (pt) 2010-03-30 2016-05-31 Novartis Ag inibidores de pkc para o tratamento de linfomade células b tendo sinalização do receptor de células b ativas crônicas
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
MX2012011912A (es) 2010-04-13 2012-11-16 Novartis Ag Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
KR20130048293A (ko) 2010-06-25 2013-05-09 노파르티스 아게 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
WO2012099581A1 (en) 2011-01-19 2012-07-26 Takeda Pharmaceutical Company Limited Dihydrofuropyrimidine compounds
CA2843887A1 (en) 2011-08-03 2013-02-07 Signal Pharmaceuticals, Llc Identification of gene expression profile as a predictive biomarker for lkb1 status
CN102911172A (zh) * 2011-08-04 2013-02-06 上海恒瑞医药有限公司 杂芳基并嘧啶类衍生物、其制备方法和用途
CN103374021B (zh) * 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
AU2013352261B2 (en) 2012-11-29 2018-05-10 Merck Patent Gmbh Azaquinazoline carboxamide derivatives
EP2986322A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
CA2908830C (en) 2013-04-17 2021-12-07 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
US9937169B2 (en) 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
PE20160041A1 (es) 2013-04-17 2016-01-28 Signal Pharm Llc FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA
JP6382948B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー 癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法
TWI631950B (zh) 2013-04-17 2018-08-11 標誌製藥公司 藉二氫吡𠯤并吡𠯤治療癌症
EP3003313A1 (en) 2013-05-29 2016-04-13 Signal Pharmaceuticals, LLC Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP2017511367A (ja) 2014-04-16 2017-04-20 シグナル ファーマシューティカルズ，エルエルシー １−エチル−７−（２−メチル−６−（１Ｈ−１，２，４−トリアゾール−３−イル）ピリジン−３−イル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン及び共形成物を含む固体形態、その組成物及び使用方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
WO2018144791A1 (en) * 2017-02-03 2018-08-09 Millennium Pharmaceuticals, Inc. Combination of vps34 inhibitors and mtor inhibitors
CN110996955A (zh) 2017-06-22 2020-04-10 细胞基因公司 以乙型肝炎病毒感染为特征的肝细胞癌的治疗
CN111315750B (zh) 2017-11-06 2022-12-23 南京明德新药研发有限公司 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
WO2021133509A1 (en) * 2019-12-27 2021-07-01 Angex Pharmaceutical, Inc. Heterocyclic compounds as mtor inhibitors
WO2024057013A1 (en) * 2022-09-12 2024-03-21 Exscientia Ai Limited Nlrp3 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) * 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4560685A (en) * 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) * 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
EP1481970B1 (de) * 1999-09-07 2006-03-22 Syngenta Participations AG Neue Herbizide
DE60144322D1 (de) * 2000-04-27 2011-05-12 Astellas Pharma Inc Kondensierte heteroarylderivate
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
GB0428475D0 (en) * 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders

Also Published As

Publication number Publication date
CA2628920C (en) 2015-12-29
AU2006318948B2 (en) 2011-02-24
EP1954699A1 (en) 2008-08-13
EP1954699B1 (en) 2012-09-19
NO341055B1 (no) 2017-08-14
TW200738706A (en) 2007-10-16
AR057626A1 (es) 2007-12-05
KR20080070079A (ko) 2008-07-29
CA2628920A1 (en) 2007-05-31
JP5161102B2 (ja) 2013-03-13
TWI452047B (zh) 2014-09-11
ECSP088536A (es) 2008-07-30
HRP20120963T1 (hr) 2012-12-31
WO2007060404A1 (en) 2007-05-31
KR101464384B1 (ko) 2014-11-21
IL191196A (en) 2016-02-29
PL1954699T3 (pl) 2013-01-31
AU2006318948A1 (en) 2007-05-31
UY29938A1 (es) 2007-06-29
JP2009516727A (ja) 2009-04-23
HK1124039A1 (en) 2009-07-03
US20080194546A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
NO20082101L (no) Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer
CY1121699T1 (el) Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
DK1261602T3 (da) Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
NO20060664L (no) N-substituerte benzimidazolyl C-kit inhibitorer
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
EA200701991A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО [1,5-a]ПИРИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
EP1724262A4 (en) 1- (2H) -ISOCHINOLONDERIVAT
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
AP2002002479A0 (en) Pteridinones as kinase inhibitors.
EA200970461A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
WO2007044724A3 (en) Aminopyrimidine, aminopyridine and aniline derivatives inhibitors of pim-i and/or pim-3
EA200600892A1 (ru) Новые хинолиновые производные
NO20082730L (no) Morfolinopyrimidinderivater og deres anvendelse i terapi
HUP0300798A2 (hu) Szubsztituált triazolopirimidin-származékok és alkalmazásuk rákellenes hatóanyagként és ezeket tartalmazó gyógyszerkészítmények
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
CO6341631A2 (es) Derivados de 1,2,4 - oxadiazol y su uso terapéutico
SE0400284D0 (sv) Novel compounds
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
NO20075409L (no) Substituerte aminoalkyl- og amidoalkyl-benzopyranderivater
TW200716650A (en) Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees